UNLABELLED: Background Associations between aplastic anemia and numerous drugs, pesticides and chemicals have been reported. However, at least 50% of the etiology of aplastic anemia remains unexplained. DESIGN AND METHODS: This was a case-control, multicenter, multinational study, designed to identify risk factors for agranulocytosis and aplastic anemia. The cases were patients with diagnosis of aplastic anemia confirmed through biopsy or bone marrow aspiration, selected through an active search of clinical laboratories, hematology clinics and medical records. The controls did not have either aplastic anemia or chronic diseases. A total of 224 patients with aplastic anemia were included in the study, each case was paired with four controls, according to sex, age group, and hospital where the case was first seen. Information was collected on demographic data, medical history, laboratory tests, medications, and other potential risk factors prior to diagnosis. RESULTS: The incidence of aplastic anemia was 1.6 cases per million per year. Higher rates of benzene exposure (>/=30 exposures per year) were associated with a greater risk of aplastic anemia (odds ratio, OR: 4.2; 95% confidence interval, CI: 1.82-9.82). Individuals exposed to chloramphenicol in the previous year had an adjusted OR for aplastic anemia of 8.7 (CI: 0.87-87.93) and those exposed to azithromycin had an adjusted OR of 11.02 (CI 1.14-108.02). Conclusions The incidence of aplastic anemia in Latin America countries is low. Although the research study centers had a high coverage of health services, the underreporting of cases of aplastic anemia in selected regions can be discussed. Frequent exposure to benzene-based products increases the risk for aplastic anemia. Few associations with specific drugs were found, and it is likely that some of these were due to chance alone.
UNLABELLED: Background Associations between aplastic anemia and numerous drugs, pesticides and chemicals have been reported. However, at least 50% of the etiology of aplastic anemia remains unexplained. DESIGN AND METHODS: This was a case-control, multicenter, multinational study, designed to identify risk factors for agranulocytosis and aplastic anemia. The cases were patients with diagnosis of aplastic anemia confirmed through biopsy or bone marrow aspiration, selected through an active search of clinical laboratories, hematology clinics and medical records. The controls did not have either aplastic anemia or chronic diseases. A total of 224 patients with aplastic anemia were included in the study, each case was paired with four controls, according to sex, age group, and hospital where the case was first seen. Information was collected on demographic data, medical history, laboratory tests, medications, and other potential risk factors prior to diagnosis. RESULTS: The incidence of aplastic anemia was 1.6 cases per million per year. Higher rates of benzene exposure (>/=30 exposures per year) were associated with a greater risk of aplastic anemia (odds ratio, OR: 4.2; 95% confidence interval, CI: 1.82-9.82). Individuals exposed to chloramphenicol in the previous year had an adjusted OR for aplastic anemia of 8.7 (CI: 0.87-87.93) and those exposed to azithromycin had an adjusted OR of 11.02 (CI 1.14-108.02). Conclusions The incidence of aplastic anemia in Latin America countries is low. Although the research study centers had a high coverage of health services, the underreporting of cases of aplastic anemia in selected regions can be discussed. Frequent exposure to benzene-based products increases the risk for aplastic anemia. Few associations with specific drugs were found, and it is likely that some of these were due to chance alone.
Authors: D W Kaufman; S Issaragrisil; T Anderson; K Chansung; T Thamprasit; J Sirijirachai; A Piankijagum; Y Porapakkham; S Vannasaeng; P E Leaverton; S Shapiro; N S Young Journal: Int J Epidemiol Date: 1997-06 Impact factor: 7.196
Authors: S Issaragrisil; K Chansung; D W Kaufman; J Sirijirachai; T Thamprasit; N S Young Journal: Am J Public Health Date: 1997-09 Impact factor: 9.308
Authors: Z Başlar; G Aktuglu; Z Bolaman; F Büyükkeçeci; S Gezer; E Kansu; R Koçak; E Ovali; S Ruacan; D Sargin; A Tunali; N Tüzüner; B Ulkü Journal: Leuk Res Date: 1997 Nov-Dec Impact factor: 3.156
Authors: S Issaragrisil; D W Kaufman; T Anderson; K Chansung; T Thamprasit; J Sirijirachai; A Piankijagum; Y Porapakkham; S Vannasaeng; P E Leaverton; S Shapiro; N S Young Journal: Blood Date: 1997-06-01 Impact factor: 22.113
Authors: D W Kaufman; J P Kelly; J M Jurgelon; T Anderson; S Issaragrisil; B E Wiholm; N S Young; P Leaverton; M Levy; S Shapiro Journal: Eur J Haematol Suppl Date: 1996
Authors: Leonardo Rodrigues de Oliveira; Thaís Camargos Ferreira; Fernando de Freitas Neves; Antônio Carlos de Oliveira Meneses Journal: Rev Bras Hematol Hemoter Date: 2013
Authors: Liliana A Zúñiga-Venegas; Carly Hyland; María Teresa Muñoz-Quezada; Lesliam Quirós-Alcalá; Mariana Butinof; Rafael Buralli; Andres Cardenas; Ricardo A Fernandez; Claudia Foerster; Nelson Gouveia; Juan P Gutiérrez Jara; Boris A Lucero; María Pía Muñoz; Muriel Ramírez-Santana; Anna R Smith; Noemi Tirado; Berna van Wendel de Joode; Gloria M Calaf; Alexis J Handal; Agnes Soares da Silva; Sandra Cortés; Ana M Mora Journal: Environ Health Perspect Date: 2022-09-29 Impact factor: 11.035